eGFR Underestimates CKD in Patients with Cancer, Study Finds
A study presented at ASN Kidney Week 2026 reveals that standard eGFR tests often underestimate chronic kidney disease in cancer patients. This inaccuracy can lead to improper chemotherapy dosing and increased toxicity risks.
Why it matters
Improving diagnostic accuracy for kidney function is critical for the safe administration of chemotherapy in oncology patients.
Creatinine-based estimated glomerular filtration rate (eGFR) substantially underestimated the prevalence of chronic kidney disease (CKD) in patients with solid tumors compared with measured GFR (mGFR), according to findings presented at ASN Kidney Week 2026 in Denver, Colorado.1,2 Adding cystatin C narrowed the gap, but agreement with mGFR remained poor, particularly at thresholds guiding chemotherapy eligibility and dosing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in